Medical News

RSS

AAPM Task Group issues new radiation guidelines for brachytherapy

Radiation dose delivered to the prostate and nearby organs in every brachytherapy procedure should be carefully analyzed using post-implant CT or MRI and uniformly documented in every patient, according to a new guideline co-authored by Yan Yu, Ph.D., director of Medical Physics in the department of Radiation Oncology at Thomas Jefferson University.

3 Nov 2009

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.

3 Nov 2009

Prasco Laboratories to provide distribution services for generic versions of Allegra-D and Drisdol

Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label.

3 Nov 2009

Modified version of Bluetooth can transfer patient data four times as fast as conventional Bluetooth

A telemedicine system based on a modified version of the Bluetooth wireless protocol can transfer patient data, such as medical images from patient to the healthcare provider's mobile device for patient assessment almost four times as fast as conventional Bluetooth and without the intermittent connectivity problems, according to a paper in the forthcoming issue of the International Journal of Medical Engineering and Informatics.

3 Nov 2009

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.

3 Nov 2009

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Community pharmacists have stepped up to meet the shortage of Tamiflu by compounding doses for children suffering from the H1N1 flu virus, but they are struggling with supply problems and insurance plans, according to the National Community Pharmacists Association.

3 Nov 2009

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

3 Nov 2009

Cuts in cancer care a move in the wrong direction of health care reform, says COA

The Community Oncology Alliance (COA) today criticized the newest round of cuts in cancer care as a move in the wrong direction of health care reform. Although not as devastating as expected, the cuts by the Centers for Medicare and Medicaid Services (CMS) will still decrease reimbursements far beyond what the U.S. cancer care delivery system, including most patients, can bear.

3 Nov 2009

Stereotactic radiosurgery effective in eliminating Parkinson's disease tremors

Stereotactic radiosurgery (SRS) offers a less invasive way to eliminate tremors caused by Parkinson's disease and essential tremor than deep brain stimulation (DBS) and radiofrequency (RF) treatments, and is as effective, according to a long-term study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

No evidence found to link decreased physical activity and spike in obesity rates among U.S. adolescents

Decreased physical activity may have little to do with the recent spike in obesity rates among U.S. adolescents, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

3 Nov 2009

State funding declines for Phoenix Academy San Diego, seeks new sources of funding

Since 1988, Phoenix Academy San Diego has helped thousands of troubled teens reclaim their lives, establishing itself as a vital county resource for at-risk youth and their families. The Academy, a residential high school for youth with substance abuse and co-occurring mental health disorders is now suffering further declines in the state funding it relies upon to operate, it was announced today by Winnie Wechsler, Executive Director for Phoenix Houses of California.

3 Nov 2009

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference.

3 Nov 2009

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

3 Nov 2009

Sales of AMD LASERS' Picasso soft tissue dental lasers triple expectations

AMD LASERS, with global headquarters in Indianapolis, IN, today announced that projected sales of the Picasso soft tissue dental lasers have more than tripled expectations in the first year. The March FDA market clearance of Picasso signaled the beginning in a series of dental laser products to be developed and launched over the next few years by the locally owned and operated company.

From AMD Lasers 3 Nov 2009

Teva Pharmaceutical Industries net sales up 25%

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2009.

3 Nov 2009

Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Quintiles today announced that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.

3 Nov 2009

Affiliated Dialysis Centers to purchase nursing home dialysis business in Chicago

Affiliated Dialysis Centers, LLC (“ADC”), an independent dialysis provider based in Illinois, today announced that a definitive agreement has been reached to purchase a nursing home dialysis business in the Chicago market.

3 Nov 2009

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

SRU Biosystems today announced that Caliper Life Sciences will use SRU Biosystems’ label-free BIND® technology to offer new functional assays as part of its Discovery Alliances and Services.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.

3 Nov 2009

Medical News

AAPM Task Group issues new radiation guidelines for brachytherapy

Tumor-penetrating microparticles may offer treatment hope for those suffering with pancreatic cancer

Prasco Laboratories to provide distribution services for generic versions of Allegra-D and Drisdol

Modified version of Bluetooth can transfer patient data four times as fast as conventional Bluetooth

Study reveals high risk of recurrence for early-stage breast cancer patients with HER2 positive tumors

Tamiflu in short supply, pharmacists compound doses for children suffering from the H1N1 flu virus

Crohn's disease drug market driven by TNF-alpha inhibitors Humira and Remicade

Cuts in cancer care a move in the wrong direction of health care reform, says COA

Stereotactic radiosurgery effective in eliminating Parkinson's disease tremors

No evidence found to link decreased physical activity and spike in obesity rates among U.S. adolescents

State funding declines for Phoenix Academy San Diego, seeks new sources of funding

Efficacy trial of the world's most clinically advanced malaria vaccine candidate underway

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sales of AMD LASERS' Picasso soft tissue dental lasers triple expectations

Teva Pharmaceutical Industries net sales up 25%

Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Affiliated Dialysis Centers to purchase nursing home dialysis business in Chicago

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

Phase 1 study of STX107 for Fragile X syndrome begins

FDA update on BYETTA injection: Amylin Pharmaceuticals and Eli Lilly respond

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News